FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants

FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants?utm_medium=email&utm_source=govdelivery FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants The U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. Abrysvo is approved for use at 32 through 36 weeks gestational age of pregnancy. Abrysvo is administered as a single dose injection into the muscle. The FDA approved Abrysvo in May for the prevention of LRTD caused by RSV in individuals 60 years of age and older.